EGRX Stock Summary and Trading Ideas (Eagle Pharmaceuticals | NASDAQ:EGRX)

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals trades on the NASDAQ stock market under the symbol EGRX.

As of April 18, 2024, EGRX stock price climbed to $4.48 with 132,846 million shares trading.

EGRX has a beta of -0.44, meaning it tends to be less sensitive to market movements. EGRX has a correlation of 0.00 to the broad based SPY ETF.

EGRX has a market cap of $58.05 million. This is considered a Micro Cap stock.

In the last 3 years, EGRX stock traded as high as $58.25 and as low as $4.10.

The top ETF exchange traded funds that EGRX belongs to (by Net Assets): VTI, IWM, VXF, AVUV, IWN.

EGRX has underperformed the market in the last year with a price return of -84.5% while the SPY ETF gained +22.3%. EGRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.8% and -7.8%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

EGRX support price is $4.11 and resistance is $4.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EGRX stock will trade within this expected range on the day.